Bellevue Group Ag Black Diamond Therapeutics, Inc. Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 8,517,839 shares of BDTX stock, worth $18.9 Million. This represents 0.62% of its overall portfolio holdings.

Number of Shares

8,517,839

Previous 8,517,839 -0.0%

Holding current value

$18.9 Million

Previous $39.7 Million 6.65%

% of portfolio

0.62%

Previous 0.66%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.67 - $5.74 $48,060 - $103,320	-18,000 Reduced 0.21%	8,517,839 $43.2 Million
Q4 2023 Feb 14, 2024	BUY	$1.77 - $3.03 $708,000 - $1.21 Million	400,000 Added 4.92%	8,535,839 $24 Million
Q2 2023 Aug 14, 2023	BUY	$1.43 - $6.18 $3.92 Million - $16.9 Million	2,740,000 Added 50.78%	8,135,839 $41.1 Million
Q1 2023 May 15, 2023	SELL	$1.35 - $3.14 $6,750 - $15,700	-5,000 Reduced 0.09%	5,395,839 $10.2 Million
Q4 2022 Feb 14, 2023	BUY	$1.27 - $2.51 $868,332 - $1.72 Million	683,726 Added 14.49%	5,400,839 $9.72 Million
Q2 2022 Aug 11, 2022	BUY	$1.5 - $3.63 $2.14 Million - $5.17 Million	1,424,113 Added 43.25%	4,717,113 $11.6 Million
Q1 2022 May 13, 2022	SELL	$2.66 - $5.61 $452,200 - $953,700	-170,000 Reduced 4.91%	3,293,000 $9.12 Million
Q2 2021 Aug 12, 2021	BUY	$12.19 - $28.17 $14.9 Million - $34.4 Million	1,220,000 Added 54.39%	3,463,000 $42.2 Million
Q1 2021 May 12, 2021	BUY	$22.23 - $34.75 $18.7 Million - $29.2 Million	840,000 Added 59.87%	2,243,000 $54.4 Million
Q2 2020 Aug 13, 2020	BUY	$22.3 - $44.8 $1.63 Million - $3.27 Million	73,000 Added 5.49%	1,403,000 $59.2 Million
Q1 2020 May 14, 2020	BUY	$18.18 - $39.48 $24.2 Million - $52.5 Million	1,330,000 New	1,330,000 $33.2 Million

Others Institutions Holding BDTX

# of Institutions

117

Shares Held

48.8M

Call Options Held

1.84M

Put Options Held

1.93M

View Full List

About Black Diamond Therapeutics, Inc.

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $80.7M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

More about BDTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Black Diamond Therapeutics, Inc. Transaction History